Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

MD Magazine

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses
MD Magazine
The study, “Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion,” was published online in JAMA Ophthalmology.


Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Stake Lowered by Tiaa Fsb
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 52 news articles »

Business Wire (press release)

Altris.AI – The New Era of Retinal Diagnosis is Coming
Business Wire (press release)
Lamellar Macular Hole;. • Pseudohole;. • Central Retinal Vein Occlusion;. • Branch Retinal Vein Occlusion;. • Retinal Artery Occlusion;. • Pigment Choroidal Nevus;. • Solar Maculopathy;. • Chorioretinal scars;. • Vitelliform Dystrophy;. • Tapetoretinal ...

and more »

FDA Headlines

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right Time
FDA Headlines
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

$5.22 EPS Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter
BharataPress
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


Korea Biomedical Review

Allergan's eye implant recalled due to foreign substance
Korea Biomedical Review
Ozurdex is implanted in the vitreous of the eye to treat macular edema following branch retinal vein occlusion (BRVO), diabetic macular edema, and noninfectious uveitis with inflammation of the posterior segment of the eye. Recalled products have ...


MedicalResearch.com (blog)

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-VGEF Therapy for Macular ...
MedicalResearch.com (blog)
Seventy-five eyes had central retinal vein occlusion (CRVO) or hemi-retinal vein occlusion (HRVO), and 72 eyes had branch retinal vein occlusion (BRVO). Among the 147 patients, the mean patient age was 68.9 years, 75 (51 percent) were female and 72 (49 ...


FDA Headlines

Is it Time to Get Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on the Radar Again?
FDA Headlines
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Global Retinal Vein Occlusions market – industry analysis, share, growth, trends and forecast from 2018-2025
Trade Market Research
Retinal vein occlusions occurs when there is a blockage of veins carrying blood with needed oxygen and nutrients to the nerve cells in the retina. Retinal vein is divided into two different types such as; central retinal vein occlusion (CRVO) and ...


Public Employees Retirement System of Ohio Purchases 223 Shares of Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Hold Rating from JPMorgan Chase & Co.
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 46 news articles »

RVC (Retinal Vein Occlusion) Market 2018 Superior Growth at a CAGR of 11.2% till 2023 | Diagnosis, Optical ...
MENAFN.COM
Global Retinal Vein Occlusion Market - Segments. The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion ...

and more »

Two-year data confirm efficacy of EYLEA® (aflibercept solution for injection) Treat and Extend dosing regimens for ...
PharmiWeb.com (press release)
... visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) and visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO); visual impairment due to diabetic macular oedema (DMO) and ...


Regeneron Pharmaceuticals (REGN) Price Target Increased to $410.00 by Analysts at Canaccord Genuity
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Odey Asset Management Group Ltd Has $2.83 Million Stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

XNewsPress

Flagship Harbor Advisors LLC Invests $159000 in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 95 news articles »

The News Partner (press release) (blog)

Global Placenta Growth Factor Market 2018 Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd
The News Partner (press release) (blog)
Applications covered in Placenta Growth Factor industry – Branch Retinal Vein Occlusion, Myopia, Neovascular Glaucoma, Others. Do Inquiry About The Report Here: www.extentresearch.com/inquiry-for-buying.html?repid=1664. Global Placenta Growth ...


Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Stake Lowered by Dai Ichi Life Insurance Company Ltd
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Marea Informative (blog)

Essex Investment Management Co. LLC Has $5.10 Million Position in Regeneron Pharmaceuticals Inc (REGN)
Marea Informative (blog)
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

The Siver Times

Ukraine has banned the popular drug
The Siver Times
with macular edema, which was caused due to occlusion of the Central retinal vein or occlusion branch retinal vein;with inflammation of the posterior segment of the eye in the form of non-infectious uveitis;violation of vision due to diabetic macular ...

and more »

PressOracle

Brokerages Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Post Earnings of $5.22 Per Share
PressOracle
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


Bel Marra Health

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment
Bel Marra Health
Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each sufferer. There are some cases where a person can recover from BRVO. Here we look at the ...


Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... branch RVO, 70 central RVO) treated with at least three anti-VEGF injections in the study eye was conducted. Available data collected for at least 6 months after the first injection included Snellen best-corrected visual acuity (BCVA), central ...

and more »

Medgadget (blog)

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch ...
Medgadget (blog)
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...


Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular ...
Dove Medical Press
Poorer final vision was associated with poorer baseline BCVA and diagnosis of central retinal vein occlusion after adjustment for age and sex (p<0.001 and 0.012, respectively). Significant elevation of IOP was noted at 3 months in the PSTA group, but ...


Asia-Pacific Placenta Growth Factor Market Report 2018
theaerospacenews.com
In this report, the Asia-Pacific Placenta Growth Factor market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Asia-Pacific Placenta Growth Factor market ...

and more »

Healthcare Sector

Worldwide Placenta Growth Factor Market: Industry Growth, Competitive Analysis, Future Prospects and Forecast 2023
Healthcare Sector
Major applications are as follows: Branch Retinal Vein Occlusion, Myopia, Neovascular Glaucoma, Others, & more. The experts within the industry have additionally attempted to investigate the export and import policies that make an immediate impact on ...


Medgadget (blog)

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and ...
Medgadget (blog)
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the ...

and more »

MD Magazine

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure
MD Magazine
Eleven patients had at least an eye with branch retinal vein occlusion. Ten eyes had age-related macular degeneration (AMD), 7 had proliferative diabetic retinopathy, 6 had central retinal vein occlusion, 5 had central serous chorioretinopathy, and 3 ...

» Load more